Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study.

[hodgkin lymphoma, classical]

The treatment and outcomes of patients with human immunodeficiency virus (HIV )-associated Hodgkin lymphoma (HL ) continue to evolve . The International Prognostic Score (IPS ) is used to predict the survival of patients with advanced -stage HL , but it has not been validated in patients with HIV infection .This was a multi-institutional , retrospective study of 229 patients with HIV-associated , advanced -stage , classical HL who received doxorubicin , bleomycin , vinblastine , and dacarbazine (ABVD ) plus combination antiretroviral therapy . Their clinical characteristics were presented descriptively , and multivariate analyses were performed to identify the factors that were predictive of response and prognostic of progression-free survival (PFS ) and overall survival (OS ).The overall and complete response rates to ABVD in patients with HIV-associated HL were 91 % and 83 %, respectively . After a median follow-up of 5 years , the 5 -year PFS and OS rates were 69 % and 78 %, respectively . In multivariate analyses , there was a trend toward an IPS score >3 as an adverse factor for PFS (hazard ratio [HR ], 1 .49 ; P =.15 ) and OS (HR , 1 .84 ; P =.06 ). A cluster of differentiation 4 (CD 4 )-positive (T -helper ) cell count <200 cells /μL was associated independently with both PFS (HR , 2 .60 ; P =.002 ) and OS (HR , 2 .04 ; P =.04 ). The CD 4 -positive cell count was associated with an increased incidence of death from other causes (HR , 2 .64 ; P =.04 ) but not with death from HL-related causes (HR , 1 .55 ; P =.32 ).The current results indicate excellent response and survival rates in patients with HIV-associated , advanced -stage , classical HL who receive ABVD and combination antiretroviral therapy as well as the prognostic value of the CD 4 -positive cell count at the time of lymphoma diagnosis for PFS and OS . Cancer 2014 . © 2014 American Cancer Society .

Diseases
Validation

Diseases presenting "cancer" symptom

achondroplasia

acute rheumatic fever

adrenal incidentaloma

alpha-thalassemia

benign recurrent intrahepatic cholestasis

cadasil

canavan disease

carcinoma of the gallbladder

cholangiocarcinoma

coats disease

congenital adrenal hyperplasia

congenital diaphragmatic hernia

cowden syndrome

cushing syndrome

cutaneous mastocytosis

dedifferentiated liposarcoma

dystrophic epidermolysis bullosa

epidermolysis bullosa simplex

erdheim-chester disease

erythropoietic protoporphyria

esophageal adenocarcinoma

esophageal carcinoma

esophageal squamous cell carcinoma

familial hypocalciuric hypercalcemia

familial mediterranean fever

gm1 gangliosidosis

heparin-induced thrombocytopenia

hereditary cerebral hemorrhage with amyloidosis

hirschsprung disease

hodgkin lymphoma, classical

inclusion body myositis

junctional epidermolysis bullosa

kabuki syndrome

kallmann syndrome

kindler syndrome

lamellar ichthyosis

liposarcoma

locked-in syndrome

lymphangioleiomyomatosis

monosomy 21

neuralgic amyotrophy

oculocutaneous albinism

oligodontia

oral submucous fibrosis

papillon-lefèvre syndrome

pendred syndrome

pleomorphic liposarcoma

primary effusion lymphoma

proteus syndrome

pyomyositis

pyruvate dehydrogenase deficiency

severe combined immunodeficiency

sneddon syndrome

systemic capillary leak syndrome

triple a syndrome

von hippel-lindau disease

waldenström macroglobulinemia

well-differentiated liposarcoma

werner syndrome

wiskott-aldrich syndrome

wolf-hirschhorn syndrome

x-linked adrenoleukodystrophy

This symptom has already been validated